Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray
27 sept. 2024 09h01 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Certification to ISO 13485 extended to also include production process Supports Bentrio growth strategy together with strategic contract...
Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia
16 sept. 2024 08h30 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Nuance Pharma successfully launched Bentrio® nasal spray for protection against airborne particles in Hong Kong and filed request for marketing...
Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark
23 août 2024 09h01 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Successful launch of Bentrio by Pharma Nordic AS in Norway in 2024Exclusive distribution agreement extended to also include Sweden and Denmark ...
Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances
16 août 2024 09h01 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Independent analytical testing of Bentrio for > 230 prohibited substances of WADA list found none of themOutcome further confirms Bentrio’s...
Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal
23 mai 2024 08h47 HE
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, May 23, 2024 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA – May 23, 2024 -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and...
Auris Medical Announces Publication of Data from Preclinical Studies with Bentrio™ Nasal Spray in Prevention and Mitigation of SARS-CoV-2
14 juil. 2021 09h00 HE
|
Auris Medical AG
Bentrio™ formulation well tolerated in vitro on human nasal epitheliumUp to 99% reduction of SARS-CoV-2 viral titer with prophylactic treatment vs. controlsViral titer reduced 12- or 14-fold vs....
Auris Medical to Initiate Market Launch of Bentrio™ Nasal Spray in Germany
28 juin 2021 08h30 HE
|
Auris Medical AG
Hamilton, Bermuda, June 28, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection,...
Auris Medical Starts Preparations for Covid-19 Trial with Bentrio in India
01 juin 2021 08h30 HE
|
Auris Medical AG
Hamilton, Bermuda, June 1, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology,...
Auris Medical Announces Completion of Bentrio Conformity Assessment Procedure for Marketing in EU
25 mai 2021 09h00 HE
|
Auris Medical AG
Meeting essential requirements for marketing BentrioTM in Europe under CE markOn track for first product launch in Europe towards end of Q2 2021 Hamilton, Bermuda, May 25, 2021 – Auris Medical...
Auris Medical Provides Update on Bentrio Program in Allergy
07 mai 2021 09h05 HE
|
Auris Medical AG
BentrioTM meets primary efficacy endpoint in clinical evaluation in allergic rhinitisClinically relevant and significant reduction in nasal symptomsSuperior efficacy ratings by patients and clinicians...